Precision Genomic Medicine in Cystic Fibrosis

Clinical and Translational Science

Volumn 8, Issue 5, 2015, Pages 606-610

  Chang, Eugene H ^a   Zabner, Joseph ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Epithelium; Genes; Genetics

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; CFTR PROTEIN, HUMAN; GENETIC MARKER;

AIRWAY OBSTRUCTION; ARTICLE; CFTR GENE; CYSTIC FIBROSIS; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MALE GENITAL SYSTEM; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; SWEAT GLAND; ANIMAL; DISEASE COURSE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN GENOME; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; GENE-ENVIRONMENT INTERACTION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84946409787     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12292     Document Type: Article

References (53)

1. Collins FS, Green ED, Guttmacher AE, Guyer MS, US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003; 422: 835-847.
2. DNA Sequencing Costs DNA Sequencing Costs. DNA Sequencing Costs. Available at: http://www.genome.gov/sequencingcosts/, Accessed December 19, 2014.
3. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al, Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153: S4-S14.
4. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005; 352: 1992-2001.
5. Cystic Fibrosis Foundation Patient Registry. Annual Data Report Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report (Cystic Fibrosis Foundation, Bethesda, MD), 2012.
6. Sosnay PR, Siklosi KR, VanGoor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45: 1160-1167.
7. Bombieri C, Claustres M, DeBoeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011; 10(Suppl 2): S86-S102.
8. Castellani C, CFTR2 team. CFTR2: how will it help care? Paediatr Respir Rev. 2013; 14(Suppl 1): 2-5.
9. Chang EH. New insights into the pathogenesis of cystic fibrosis sinusitis. Int Forum Allergy Rhinol. 2014; 4: 132-137.
10. Chang EH, Pezzulo AA, Meyerholz DK, Potash AE, Wallen TJ, Reznikov LR, Sieren JC, Karp PH, Ernst S, Moninger TO, et al. Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope. 2012; 122: 1898-1905.
11. Ferril GR, Nick JA, Getz AE, Barham HP, Saavedra MT, Taylor-Cousar JL, Nichols DP, Curran-Everett D, Kingdom TT, Ramakrishnan VR. Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes. Int Forum Allergy Rhinol. 2014; 4: 915-920.
12. Woodworth BA, Ahn C, Flume PA, Schlosser RJ. The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007; 21: 122-127.
13. Berkhout MC, vanRooden CJ, Rijntjes E, Fokkens WJ, el Bouazzaoui LH, Heijerman HGM. Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype? J Cyst Fibros. 2014; 13: 442-448.
14. Wang X, Moylan B, Leopold DA, Kim J, Rubenstein RC, Togias A, Proud D, Zeitlin PL, Cutting GR. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA. 2000; 284: 1814-1819.
15. Wang X, Kim J, McWilliams R, Cutting GR. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch Otolaryngol Head Neck Surg. 2005; 131: 237-240.
16. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet. 1996; 4: 65-73.
17. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000; 67: 117-133.
18. Gaskin K, Gurwitz D, Durie P, Corey M, Levison H, Forstner G. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr. 1982; 100: 857-862.
19. Tzetis M, Efthymiadou A, Strofalis S, Psychou P, Dimakou A, Pouliou E, Doudounakis S, Kanavakis E. CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet. 2001; 108: 216-221.
20. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gilè LS, Luisetti M, Pignatti PF. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet. 1998; 103: 718-722.
21. Casals T, De-Gracia J, Gallego M, Dorca J, Rodríguez-Sanchón B, Ramos MD, Giménez J, Cisteró-Bahima A, Olveira C, Estivill X. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? Clin Genet. 2004; 65: 490-495.
22. Kerem BS, Buchanan JA, Durie P, Corey ML, Levison H, Rommens JM, Buchwald M, Tsui LC. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet. 1989; 44: 827-834.
23. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, Durie P. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. 1992; 50: 1178-1184.
24. Cohn JA, Neoptolemos JP, Feng J, Yan J, Jiang Z, Greenhalf W, McFaul C, Mountford R, Sommer SS. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat. 2005; 26: 303-307.
25. Kerem E, Corey M, Kerem B, Durie P, Tsui LC, Levison H. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr. 1989; 114: 767-773.
26. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008; 321: 1837-1841.
27. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science. 1994; 266: 1705-1708.
28. Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp PH, Samuel MS, Reznikov LR, Rector MV, Gansemer ND, et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest. 2013; 123: 2685-2693.
29. Houwen RH, vander Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, Robberecht E, Colombo C, Sinaasappel M, Wilschanski M, ESPGHAN Cystic Fibrosis Working Group. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010; 50: 38-42.
30. Kleczkowska A, Fryns JP, Steeno O, vanden Berghe H. On the familial occurrence of congenital bilateral absence of vas deferens. Clin Genet. 1989; 35: 268-271.
31. Claustres M. Molecular pathology of the CFTR locus in male infertility. Reprod Biomed Online. 2005; 10: 14-41.
32. Zielenski J, Patrizio P, Corey M, Handelin B, Markiewicz D, Asch R, Tsui LC. CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet. 1995; 57: 958-960.
33. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA. 1992; 267: 1794-1797.
34. Busch R. On the history of cystic fibrosis. Acta Univ Carol Med (Praha). 1990; 36: 13-15.
35. Feldmann D, Couderc R, Audrezet M-P, Ferec C, Bienvenu T, Desgeorges M, Claustres M, Mittre H, Blayau M, Bozon D, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat. 2003; 22: 340.
36. Santis G, Osborne L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet. 1990; 336: 1081-1084.
37. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. 1996; 12: 280-287.
38. Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T, Larriba S, Mercier B, Cutting GR, Krebsova A, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet. 1999; 22: 128-129.
39. Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet. 2014; 133: 151-161.
40. Smyth A, O'Hea U, Williams G, Smyth R, Heaf D. Passive smoking and impaired lung function in cystic fibrosis. Arch Dis Child. 1994; 71: 353-354.
41. Rubin BK. Exposure of children with cystic fibrosis to environmental tobacco smoke. N Engl J Med. 1990; 323: 782-788.
42. Kovesi T, Corey M, Levison H. Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis. 1993; 148: 1266-1271.
43. Raju SV, Tate JH, Peacock SKG, Fang P, Oster RA, Dransfield MT, Rowe SM. Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. Respir Res. 2014; 15: 18.
44. Eckford PDW, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012; 287: 36639-36649.
45. VanGoor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009; 106: 18825-18830.
46. Chang EH, Tang XX, Shah VS, Launspach JL, Ernst SE, Hilkin B, Karp PH, Abou Alaiwa MH, Graham SM, Hornick DB, et al. Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor. Int Forum Allergy Rhinol. 2015; 5: 178-181.
47. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363: 1991-2003.
48. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, Moran A. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diab. 2013; 14: 417-421.
49. Jih K-Y, Hwang T-C. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013; 110: 4404-4409.
50. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012; 67: 12-18.
51. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol. 2013; 9: 444-454.
52. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, Riordan JR. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 2013; 27: 536-545.
53. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D, VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2: 527-538.